Skip to main content

Research Repository

Advanced Search

All Outputs (87)

Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum) (2022)
Journal Article
Adams, L., Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Van-Tam, J. S., …Abhishek, A. (2022). Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum). British Journal of Dermatology, 188(2), 297-299. https://doi.org/10.1093/bjd/ljac061

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative (2022)
Journal Article
Leshem, Y. A., Chalmers, J. R., Apfelbacher, C., Katoh, N., Gerbens, L. A., Schmitt, J., …Simpson, E. L. (2022). Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. JAMA Dermatology, 158(12), 1429-1435. https://doi.org/10.1001/jamadermatol.2022.4211

Importance: Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list of validated, feas... Read More about Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.

Is routine laboratory testing in healthy young patients taking isotretinoin necessary – a critically appraised topic (2022)
Journal Article
Affleck, A., Jackson, D., Williams, H. C., Chavez, P., & Albrecht, J. (2022). Is routine laboratory testing in healthy young patients taking isotretinoin necessary – a critically appraised topic. British Journal of Dermatology, 187(6), 857-865. https://doi.org/10.1111/bjd.21840

Clinical question: Is monitoring of liver function, lipids and full blood count necessary in healthy people taking isotretinoin? Background: Routine blood testing was recommended in the original licence for Roaccutane™ (isotretinoin) in 1983. In r... Read More about Is routine laboratory testing in healthy young patients taking isotretinoin necessary – a critically appraised topic.

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial (2022)
Journal Article
Abhishek, A., Boyton, R. J., Peckham, N., McKnight, Á., Coates, L. C., Bluett, J., …Cook, J. A. (2022). Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine, 10(9), 840-850. https://doi.org/10.1016/S2213-2600%2822%2900186-2

Background: Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses against the... Read More about Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.

On the definition of dermatological disease. Part 1: conceptual frameworks (2022)
Journal Article
Williams, H. C. (2022). On the definition of dermatological disease. Part 1: conceptual frameworks. Clinical and Experimental Dermatology, 47(10), 1805-1811. https://doi.org/10.1111/ced.15279

Little attention is paid to disease definition in dermatology and how such definitions come about, yet defining a disease is a fundamental step upon which all subsequent clinical management and prognostic judgements depend. Developing diagnostic crit... Read More about On the definition of dermatological disease. Part 1: conceptual frameworks.

Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review (2022)
Journal Article
Jones, O. T., Matin, R. N., van der Schaar, M., Prathivadi Bhayankaram, K., Ranmuthu, C. K. I., Islam, M. S., …Walter, F. M. (2022). Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review. The Lancet. Digital Health, 4(6), e466-e476. https://doi.org/10.1016/s2589-7500%2822%2900023-1

Skin cancers occur commonly worldwide. The prognosis and disease burden are highly dependent on the cancer type and disease stage at diagnosis. We systematically reviewed studies on artificial intelligence and machine learning (AI/ML) algorithms that... Read More about Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review.

Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial (2022)
Journal Article
Ridd, M. J., Santer, M., MacNeill, S. J., Sanderson, E., Wells, S., Webb, D., …Thomas, K. S. (2022). Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child and Adolescent Health, 6(8), 522-532. https://doi.org/10.1016/S2352-4642%2822%2900146-8

Background: To our knowledge, there are no trials comparing emollients commonly used for childhood eczema. We aimed to compare the clinical effectiveness and safety of the four main emollient types: lotions, creams, gels, and ointments. Methods: We d... Read More about Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial.

Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum (2022)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Riley, R., Van Der Windt, D., …Abhishek, A. (2022). Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatology Advances in Practice, 6(2), Article rkac046. https://doi.org/10.1093/rap/rkac046

Objective: The aim was to examine the incidence and pattern of MMF discontinuation associated with abnormal monitoring blood-test results. Methods: Data from people prescribed MMF for common inflammatory conditions in the Clinical Practice Research D... Read More about Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) (2022)
Journal Article
Abhishek, A., Boyton, R. J., McKnight, Á., Coates, L. C., Bluett, J., Barber, V., …Cook, J. A. (2022). Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study). BMJ Open, 12(5), Article e062599. https://doi.org/10.1136/bmjopen-2022-062599

Introduction It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexa... Read More about Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).

Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema (2022)
Journal Article
Greenwell, K., Ghio, D., Sivyer, K., Steele, M., Teasdale, E., Ridd, M. J., …Muller, I. (2022). Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema. BMJ Open, 12(4), Article e056867. https://doi.org/10.1136/bmjopen-2021-056867

Objectives To describe the development of Eczema Care Online (ECO), an online behaviour change intervention for young people with eczema (phase I); and explore and optimise the acceptability of ECO among this target group using think-aloud interviews... Read More about Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema.

Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building (2022)
Journal Article
Layfield, C. P., Williams, H. C., & The UK Dermatology Clinical Trials Network. (2022). Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building. Clinical and Experimental Dermatology, 47(6), 1060-1067. https://doi.org/10.1111/ced.15132

In Part 1 of this 2-part review of the 20th anniversary of the UK Dermatology Clinical Trials Network (UK DCTN), we described its role in developing and supporting clinical trial proposals, elaborating on structure, process and clinical trials activi... Read More about Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 2: education, training and capacity building.

Avoidable research waste in dermatology: what are the solutions? (2022)
Journal Article
Williams, H. C. (2022). Avoidable research waste in dermatology: what are the solutions?. British Journal of Dermatology, 186(4), 599-601. https://doi.org/10.1111/bjd.20755

In the last editorial, I provided examples of research waste in dermatology and suggested that it was due to a system failure rather than just a few “bad apples”. Here, I focus on possible solutions, mainly in relation to clinical trials, building on... Read More about Avoidable research waste in dermatology: what are the solutions?.

Avoidable research waste in dermatology: what are the solutions? (2022)
Journal Article
Williams, H. C. (2022). Avoidable research waste in dermatology: what are the solutions?. British Journal of Dermatology, 186(4), 599-601. https://doi.org/10.1111/bjd.20755

In the last editorial, I provided examples of research waste in dermatology and suggested that it was due to a system failure rather than just a few “bad apples”. Here, I focus on possible solutions, mainly in relation to clinical trials, building on... Read More about Avoidable research waste in dermatology: what are the solutions?.

The HOME Core outcome set for clinical trials of atopic dermatitis (2022)
Journal Article
Williams, H. C., Schmitt, J., Thomas, K. S., Spuls, P. I., Simpson, E. L., Apfelbacher, C. J., …Boers, M. (2022). The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 149(6), 1899-1911. https://doi.org/10.1016/j.jaci.2022.03.017

Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence in atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale fo... Read More about The HOME Core outcome set for clinical trials of atopic dermatitis.

Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics (2022)
Journal Article
Bosma, A. L., Ascott, A., Iskandar, R., Farquhar, K., Matthewman, J., Langendam, M. W., …Middelkamp-Hup, M. A. (2022). Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. Journal of the European Academy of Dermatology and Venereology, 36(6), 807-819. https://doi.org/10.1111/jdv.18008

Atopic dermatitis is a heterogeneous disease, accompanied by a wide variation in disease presentation and the potential to identify many phenotypes that may be relevant for prognosis and treatment. We aimed to systematically review previously reporte... Read More about Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics.

Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials (2022)
Journal Article
Williams, H. C., McPhee, M., Layfield, C., & The UK Dermatology Clinical Trials Network. (2022). Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials. Clinical and Experimental Dermatology, 47(6), 1048-1059. https://doi.org/10.1111/ced.15140

The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high-quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosop... Read More about Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials.